Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Disc Medicine, Inc.GMTX · Entity 2273 | Chief People Officer | February 05, 2021 | April 07, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Disc Medicine, Inc.
Report date February 05, 2021 · Filed April 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.66 · Expires 2031-02-04 | Direct | 77,450 |
Reported balance
After 2021-02-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-05 · Grant · Acquired 77,450 · Balance 77,450 F1: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, February 5, 2021 with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, February 5, 2021 with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 23, 2021 Filed Feb 25, 2021 16:52 UTC | Disc Medicine, Inc. GMTX · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 25,489 | $0.00 Strike: $14.21 | $0.00 |
DisclosureSEC source: 0001213900-21-011690 · ownership.xml · derivative · entry 1 Redmond Precillia · CIK 0001843163 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,489 Underlying: Common Stock · 25,489 shares Expires 2031-02-22 F1 · derivative.exercise_date: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, February 23, 2021 with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company. Read SEC document |
| February 05, 2021 Filed Apr 7, 2021 16:04 UTC | Disc Medicine, Inc. GMTX · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 77,450 | $0.00 Strike: $12.66 | $0.00 |
DisclosureSEC source: 0001213900-21-020624 · ownership.xml · derivative · entry 1 Redmond Precillia · CIK 0001843163 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,450 Underlying: Common Stock · 77,450 shares Expires 2031-02-04 F1 · derivative.exercise_date: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, February 5, 2021 with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.